{
    "id": "5e49c5336d0a277941000011",
    "question": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents and find any information related to LY6K and its association with non-small cell lung cancer (NSCLC) prognosis. After reviewing the documents, I found that there is limited information about LY6K in the context of NSCLC. However, I found information about LY6K in the context of other cancers, such as breast cancer. In breast cancer, LY6K is a member of the immunoglobulin superfamily and has been implicated in cancer progression and metastasis. But I did not find any information about LY6K in NSCLC. Therefore, based on the available information, I cannot determine if overexpression of LY6K is associated with better prognosis for NSCLC patients. The correct answer would depend on specific research or studies that investigate LY6K in NSCLC. Since I couldn't find any relevant information, I will choose the option that indicates there is no clear association based on the provided documents.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_6033",
            "title": "Pharmacology_Katzung",
            "content": "Lung cancer is divided into two main histopathologic subtypes, non-small cell and small cell. Non-small cell lung cancer (NSCLC) makes up about 75\u201380% of all cases of lung cancer, and this group includes adenocarcinoma, squamous cell cancer, and large cell cancer, while small cell lung cancer (SCLC) makes up the remaining 20\u201325%. When NSCLC is diagnosed in an advanced stage with metastatic disease, the prognosis is extremely poor, with a median survival of about 8 months. It is clear that prevention (primarily through avoidance of cigarette smoking) and early detection remain the most important means of control. When diagnosed at an early stage, surgical resection results in patient cure. Moreover, recent studies have shown that adjuvant platinum-based chemotherapy provides a survival benefit in patients with pathologic stage IB, II, and IIIA disease. However, in most cases, distant metastases have occurred at the time of diagnosis. In certain instances, radiation therapy can be"
        },
        {
            "id": "InternalMed_Harrison_6813",
            "title": "InternalMed_Harrison",
            "content": "Although response rates with EGFR TKI therapy are clearly superior in patients with lung tumors harboring activating EGFR kinase domain mutations, the EGFR TKI erlotinib is also FDA approved for secondand third-line therapy in patients with advanced NSCLC irrespective of tumor genotype. The reason for this apparent discrepancy is that erlotinib was initially evaluated in lung cancer before the discovery of EGFR activating mutations. In fact, EGFR mutations were initially identified in lung cancer by studying the tumors of patients who had dramatic responses to this agent. With the rapid pace of scientific discovery, additional driver mutations in lung cancer have been identified and targeted therapeutically with impressive clinical results. For example, chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2 have been found in \u223c3\u20137% of NSCLC. The result of these ALK rearrangements is hyperactivation of the ALK TK domain. Similar to"
        },
        {
            "id": "Pathology_Robbins_3265",
            "title": "Pathology_Robbins",
            "content": "Until recently, carcinomas of the lung were classified into two broad groups: small cell lung cancer (SCLC) and non\u2013small cell lung cancer (NSCLC), the latter including adenocarcinoma, squamous and large cell carcinoma, and large cell neuroendocrine carcinomas. This classification has been recently replaced by a 2015 World Health Organization classification (a simplified version of which is shown in Table 13.6). The reason for this historic division is that virtually all SCLCs have metastasized by the time of diagnosis. Therefore, they are best treated with systemic chemotherapy, with or without radiation therapy. By contrast, NSCLCs are more likely to be resectable and usually respond poorly to conventional chemotherapy. However, therapies are now available that target specific oncoproteins that are found in a subset of NSCLC, mainly adenocarcinomas but also squamous cell carcinomas. Thus, if adequate tissue is available, NSCLC is subjected to molecular analysis to determine if"
        },
        {
            "id": "InternalMed_Harrison_6297",
            "title": "InternalMed_Harrison",
            "content": "While apoptotic mechanisms are important in regulating cellular proliferation and the behavior of tumor cells in vitro, in vivo it is unclear whether all of the actions of chemotherapeutic agents to cause cell death can be attributed to apoptotic mechanisms. However, changes in molecules that regulate apoptosis are correlated with clinical outcomes (e.g., bcl2 overexpression in certain lymphomas conveys poor prognosis; proapoptotic bax expression is associated with a better outcome after chemotherapy for ovarian carcinoma). A better understanding of the relationship of cell death and cell survival mechanisms is needed."
        },
        {
            "id": "Immunology_Janeway_4129",
            "title": "Immunology_Janeway",
            "content": "the activity of a cytotoxic cell, toxin, or even radioactive nuclide specifically to the tumor (Fig. 16.19). Some of the cell-surface molecules targeted in clinical trials are shown in Fig. 16.20, and some of these treatments have now been licensed. Striking improvements in survival have been reported for breast cancer patients treated with the monoclonal antibody trastuzumab (Herceptin), which targets the receptor HER-2/neu. This receptor is overexpressed in about one-quarter of breast cancer patients and is associated with a poor prognosis."
        },
        {
            "id": "InternalMed_Harrison_6811",
            "title": "InternalMed_Harrison",
            "content": "Targeted Therapies for Select Molecular Cohorts of NSCLC As the efficacy of traditional cytotoxic chemotherapeutic agents plateaued in NSCLC, there was a critical need to define novel therapeutic treatment strategies. These novel strategies have largely been based on the identification of somatic driver mutations within the tumor. These driver mutations occur in genes encoding signaling proteins that, when aberrant, drive initiation and maintenance of tumor cells. Importantly, driver mutations can serve as Achilles\u2019 heels for tumors, if their gene products can be targeted therapeutically with small-molecule inhibitors. For example, EGFR mutations have been detected in 10\u201315% of North American patients diagnosed with NSCLC. EGFR mutations are associated with younger age, light (<10 pack-year) and nonsmokers, and adenocarcinoma histology. Approximately 90% of these mutations are exon 19 deletions or exon 21 L858R point mutations within the EGFR TK domain, resulting in hyperactivation of"
        },
        {
            "id": "InternalMed_Harrison_6803",
            "title": "InternalMed_Harrison",
            "content": "18.6 aEnrolled selected patients: 18 years of age or older, had histologic or cytologically confirmed stage IIIB or IV non-small-cell lung cancer with histologic features of adenocarcinoma (including bronchioloalveolar carcinoma), were nonsmokers (defined as patients who had smoked <100 cigarettes in their lifetime) or former light smokers (those who had stopped smoking at least 15 years previously and had a total of \u226410 pack-years of smoking), and had had no previous chemotherapy or biologic or immunologic therapy."
        },
        {
            "id": "Cell_Biology_Alberts_5150",
            "title": "Cell_Biology_Alberts",
            "content": "18\u20132 Mammalian cells that do not have cytochrome c should be resistant to apoptosis induced by DNA damage. Discuss the following problems. 18\u20133 One important role of Fas and Fas ligand is to mediate the elimination of tumor cells by killer lymphocytes. In a study of 35 primary lung and colon tumors, half the tumors were found to have amplified and overexpressed a gene for a secreted protein that binds to Fas ligand. How do you suppose that overexpression of this protein might contribute to the survival of these tumor cells? Explain your reasoning."
        },
        {
            "id": "First_Aid_Step2_1093",
            "title": "First_Aid_Step2",
            "content": "Small cell lung cancer (SCLC): Highly correlated with cigarette exposure. Central location. Neuroendocrine origin; associated with paraneoplastic syndromes (see Table 2.15-7). Metastases are often found on presentation (intrathoracic and extrathoracic sites such as brain, liver, and bone). Non\u2013small cell lung cancer (NSCLC): Less likely to metastasize. TAB LE 2.1 5-7. Paraneoplastic Syndromes of Lung Cancer Adenocarcinoma: The most common lung cancer; peripheral location. Includes bronchoalveolar carcinoma, which is associated with multiple nodules, interstitial infltration, and prolifc sputum production but is not associated with smoking. Squamous cell carcinoma: Central location; 98% are seen in smokers. Large cell/neuroendocrine carcinomas: Least common; associated with a poor prognosis. Presents with cough, hemoptysis, dyspnea, wheezing, postobstructive pneumonia, chest pain, weight loss, and possible abnormalities on respiratory exam (crackles, atelectasis)."
        },
        {
            "id": "Pathology_Robbins_3289",
            "title": "Pathology_Robbins",
            "content": "Table 13.7 Comparison of Small Cell Lung Carcinoma and Non\u2013Small Cell Lung Carcinoma (Adenocarcinoma and Squamous Cell Carcinoma) Forexample,densecoregranulesonelectronPresentAbsentmicroscopy;expressionofchromogranin,synaptophysin,andCD56 Epithelialmembraneantigen,carcinoembryonicantigen,PresentPresentandcytokeratinintermediatefilaments EGFR mutationsAbsent~20%(adenocarcinomas,nonsmokers,women) ALK rearrangementsAbsent4%\u20136%adenocarcinomas,nonsmokers,oftenhavesignetringmorphology http://ebooksmedicine.net neoantigens), and represent a hopeful new avenue for therapy."
        },
        {
            "id": "InternalMed_Harrison_6694",
            "title": "InternalMed_Harrison",
            "content": "a lepidicor papillary-predominant pattern, most adenocarcinoma subtypes can harbor EGFR or KRAS mutations. The same is true of ALK, RET, and ROS1 rearrangements. What was previously termed mucinous bronchioloalveolar carcinoma is now called invasive mucinous adenocarcinoma. These tumors generally lack EGFR mutations and show a strong correlation with KRAS mutations. Overall, the revised WHO reclassification of lung cancer addresses important advances in diagnosis and treatment, most importantly, the critical advances in understanding the specific genes and molecular pathways that initiate and sustain lung tumorigenesis resulting in new \u201ctargeted\u201d therapies with improved specificity and better antitumor efficacy."
        },
        {
            "id": "Surgery_Schwartz_5004",
            "title": "Surgery_Schwartz",
            "content": "2009;35(5):775-780; discussion 780. 56. Fuwa N, Mitsudomi T, Daimon T, et al. Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancer\u2013from studies of 604 surgical cases. Lung Cancer. 2007;57(3):311-316. 57. Fernando HC, De Hoyos A, Landreneau RJ, et al. Radiofre-quency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg. 2005;129(3):639-644. 58. Pennathur A, Luketich JD, Abbas G, et al. Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg. 2007;134(4):857-864. 59. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofre-quency ablation of pulmonary tumours: a prospective, inten-tion-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9(7):621-628. 60. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung car-cinoma:"
        },
        {
            "id": "Immunology_Janeway_4114",
            "title": "Immunology_Janeway",
            "content": "The third category is the \u2018differentiation antigens\u2019 encoded by genes that are expressed only in particular types of tissues. Examples of these are the differentiation antigens expressed in melanocytes and melanoma cells, which include several proteins in the pathways that produce the black pigment melanin, and the CD19 antigen expressed by B cells. The fourth category consists of antigens that are strongly overexpressed in tumor cells compared with their normal counterparts. An example is HER-2/neu (also known as c-Erb-2), which is a receptor tyrosine kinase homologous to the epidermal growth factor receptor. HER-2/neu is overexpressed in many adenocarcinomas, including breast and ovarian cancers, where it is associated with a poor clinical prognosis. CD8 T lymphocytes have been found infiltrating solid tumors overexpressing HER-2/neu but are not capable of destroying such tumors in vivo. The fifth category of tumor rejection antigens consists of molecules that display abnormal"
        },
        {
            "id": "InternalMed_Harrison_6690",
            "title": "InternalMed_Harrison",
            "content": "Neoplasms of the Lung 508 chemotherapy agents performed quite differently in squamous carcinomas versus adenocarcinomas, firmly established the need for modifications in the then-existing 2004 WHO lung cancer classification system. The revised 2011 classification system, developed jointly by the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society, provides an integrated approach to the classification of lung adenocarcinomas that includes clinical, molecular, radiographic, and pathologic information. It also recognizes that most lung cancers present in an advanced stage and are often diagnosed based on small biopsies or cytologic specimens, rendering clear histologic distinctions difficult if not impossible. Previously, in the 2004 classification system, tumors failing to show definite glandular or squamous morphology in a small biopsy or cytologic specimen were simply classified as non-small-cell carcinoma, not"
        },
        {
            "id": "InternalMed_Harrison_6812",
            "title": "InternalMed_Harrison",
            "content": "and nonsmokers, and adenocarcinoma histology. Approximately 90% of these mutations are exon 19 deletions or exon 21 L858R point mutations within the EGFR TK domain, resulting in hyperactivation of both EGFR kinase activity and downstream signaling. Lung tumors that harbor activating mutations within the EGFR kinase domain display high sensitivity to small-molecule EGFR TKIs. Erlotinib and afatinib are FDA-approved oral small-molecule TKIs that inhibit EGFR. Outside the United States, gefitinib also is available. Several large, international, phase III studies have demonstrated improved response rates, progression-free survival, and overall survival in patients with EGFR mutation\u2013positive NSCLC patients treated with an EGFR TKI as compared with standard first-line chemotherapy regimens (Table 107-13)."
        },
        {
            "id": "InternalMed_Harrison_6816",
            "title": "InternalMed_Harrison",
            "content": "Most of these mutations are present in adenocarcinoma; however, mutations that may be linked to future targeted therapies in squamous cell carcinomas are emerging. In addition, there are active research efforts aimed at defining novel targetable mutations in lung cancer as well as defining mechanisms of acquired resistance to small-molecule inhibitors used in the treatment of patients with NSCLC. to supportive care alone. As first-line chemotherapy regimens improve, a substantial number of patients will maintain a good performance status and a desire for further therapy when they develop recurrent disease. Currently, several agents are FDA approved for second-line use in NSCLC including docetaxel, pemetrexed, erlotinib (approved for second-line therapy regardless of tumor genotype), and crizotinib (for patients with ALK -mutant lung cancer only). Most of the survival benefit for any of these agents is realized in patients who maintain a good performance status."
        },
        {
            "id": "Gynecology_Novak_6911",
            "title": "Gynecology_Novak",
            "content": "Table 36.2 Staging Procedures a Allowed by the International Federation of Gynecology and Obstetrics (FIGO). bInformation that is not allowed by FIGO to change the clinical stage. carcinoma should be reserved for lesions resembling oat cell carcinoma of the lung. Small cell anaplastic carcinoma infiltrates diffusely and consists of tumor cells that have scanty cytoplasm, round to oval small nuclei, coarsely granular chromatin, and high mitotic activity. The nucleoli are absent or small. Immunohistochemistry or electron microscopy can differentiate the small cell neuroendocrine tumors. Patients with the large cell type of carcinoma, with or without keratinization, have a better prognosis than those with the small cell variant. Small cell anaplastic carcinomas behave more aggressively than poorly differentiated squamous carcinomas that contain small cells. Infiltration of parametrial tissue and pelvic lymph node metastasis affect the prognosis."
        },
        {
            "id": "Surgery_Schwartz_2385",
            "title": "Surgery_Schwartz",
            "content": "J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932-20937. 165. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26. 166. Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplifica-tion: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2:922-933. 167. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS muta-tions and acquired resistance to anti-EGFR therapy in colorec-tal cancer. Nature. 2012;486:532-536. 168. Mundt A, Roeske J, Weichelbaum R. Principles of radiation oncology. In: Bast R, Kuff D, Pollock R, eds. Cancer Medi-cine. Hamilton: B.C. Decker Inc; 2000:465. 169. Raju MR, Carpenter SG. A heavy"
        },
        {
            "id": "Surgery_Schwartz_4499",
            "title": "Surgery_Schwartz",
            "content": "resection for early stage lung cancer in inoperable patients. While premature, ablative techniques may ultimately be shown to have efficacy equivalent to lobectomy for the pri-mary treatment of very small peripheral early-stage lung cancers and become primary therapy, even in operable patients, although limited resection with wedge (at least 2 cm margin and at least 1:1 tumor/margin ratio) and seg-mentectomy provide better margins of treatment and nodal sampling ensures occult nodal metastasis are identified. Multidisciplinary collaboration among thoracic surgery, interventional radiology/pulmonology, and radiation oncol-ogy is required to ensure that development of these ablative techniques occurs through properly designed and well-con-trolled prospective studies and will ensure that patients receive the best available therapy, regardless of whether it is surgical resection or ablative therapy.8 The term non\u2013small cell lung carcinoma (NSCLC) includes many tumor cell types, including"
        },
        {
            "id": "InternalMed_Harrison_6373",
            "title": "InternalMed_Harrison",
            "content": "tyrosine kinase. In early clinical trials, gefitinib showed evidence of responses in a small fraction of patients with non-small-cell lung cancer (NSCLC). Side effects were generally acceptable, consisting mostly of rash and diarrhea. Subsequent analysis of responding patients revealed a high frequency of activating mutations in the EGF receptor. Patients with such activating mutations who initially responded to gefitinib but who then had progression of the disease then acquired additional mutations in the enzyme, analogous functionally to mutational variants responsible for imatinib resistance in CML. Erlotinib is another EGF receptor tyrosine kinase antagonist with a superior outcome in clinical Chapter 103e Principles of Cancer Treatment Temsirolimus Renal cell carcinoma, second line or poor prognosis Stomatitis Thrombocytopenia Nausea Anorexia, fatigue Metabolic (glucose, lipid)"
        },
        {
            "id": "Pathology_Robbins_1305",
            "title": "Pathology_Robbins",
            "content": "cell proliferation, they tend to be indolent (slow-growing). In other tumors such as chronic lymphocytic leukemia (Chapter 12), it appears that BCL2 is upregulated because of loss of expression of specific micro-RNAs that normally dampen BCL2 expression. Many other mechanisms leading to overexpression of anti-apoptotic members of the BCL2 family have been described, particularly in the setting of resistance to chemotherapy. For example, amplification of the MCL1 gene is seen in a subset of lung and breast cancers."
        },
        {
            "id": "InternalMed_Harrison_6704",
            "title": "InternalMed_Harrison",
            "content": "in lung adenocarcinoma include the GTPase KRAS, the serine-threonine kinase BRAF, and the lipid kinase PIK3CA. More recently, more subsets of lung adenocarcinoma have been identifed as defined by the presence of specific chromsomal rearrangements resulting in the abberant activation of the TKs ALK, ROS1, and RET. Notably, most driver mutations in lung cancer appear to be mutually exclusive, suggesting that acquisition of one of these mutations is sufficient to drive tumorigenesis. Although driver mutations have mostly been found in adenocarinomas, three potential molecular targets recently have been identified in squamous cell lung carcinomas: FGFR1 amplification, DDR2 mutations, and PIK3CA mutations/PTEN loss (Table 107-1). Together, these potentially \u201cactionable\u201d defects occur in up to 50% of squamous carcinomas."
        },
        {
            "id": "Pathology_Robbins_3268",
            "title": "Pathology_Robbins",
            "content": "A subset of adenocarcinomas (about 10% in whites and 30% in Asians), particularly those arising in nonsmoking women, harbor mutations that activate the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that stimulates downstream pro-growth pathways involving RAS, PI3K, and other signaling molecules. Of note, these tumors are sensitive to drugs that inhibit EGFR signaling, although the response is often short-lived. EGFR and KRAS mutations (in 30% of adenocarcinomas) are mutually exclusive, as might be expected since KRAS lies downstream of EGFR. Other \u201ctargetable\u201d mutations have been described in a low frequency of adenocarcinomas (4% to 6% overall), including mutations that activate other tyrosine kinases, including ALK, ROS1, HER2, or c-MET. Each of these kinases is optimally targeted by a different drug, which has spurred a new era of \u201cpersonalized\u201d lung cancer treatment, in which the genetics of the tumor guide therapy."
        },
        {
            "id": "InternalMed_Harrison_21315",
            "title": "InternalMed_Harrison",
            "content": "The development of neoplastic meningitis usually occurs in the setting of uncontrolled cancer outside the CNS; thus, prognosis is poor (median survival 10\u201312 weeks). However, treatment of the neoplastic meningitis may successfully alleviate symptoms and control the CNS spread. Intrathecal chemotherapy, usually methotrexate, cytarabine, or thiotepa, is delivered by lumbar puncture or by an intraventricular reservoir (Ommaya). An extended-release preparation of cytarabine (Depocyte) has a longer half-life and is more effective than other formulations. Among solid tumors, breast cancer responds best to therapy. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may be effective in non-small-cell lung cancer patients with EGFR mutations and leptomeningeal involvement. Patients with neoplastic meningitis from either acute leukemia or lymphoma may be cured of their CNS disease if the systemic disease can be eliminated."
        },
        {
            "id": "InternalMed_Harrison_8739",
            "title": "InternalMed_Harrison",
            "content": "Treatment regimens appropriate for other aggressive lymphomas, such as diffuse large B-cell lymphoma, should be used in patients with anaplastic large T/null-cell lymphoma, with the exception that the B-cell\u2013specific antibody, rituximab, is omitted. Surprisingly, given the anaplastic appearance, this disorder has the best survival rate of any aggressive lymphoma. The 5-year survival is >75%. While traditional prognostic factors such as the IPI predict treatment outcome, overexpression of the ALK protein is an important prognostic factor, with patients overexpressing this protein having a superior treatment outcome. The ALK inhibitor crizotinib appears highly active as well. In addition, the CD30 immunotoxin, brentuximab vedotin, is active in the disease."
        },
        {
            "id": "Surgery_Schwartz_2384",
            "title": "Surgery_Schwartz",
            "content": "K. Drug resistance and its clinical circum-vention. In: Bast R, Kufe D, Pollock R, eds. Cancer Medicine. Hamilton: B.C. Decker, Inc; 2000:539. 161. Mittendorf EA, Wu Y, Scaltriti M, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009;15:7381-7388. 162. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73. 163. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplifi-cation leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-1043.Brunicardi_Ch10_p0305-p0354.indd 35322/02/19 2:14 PM 354BASIC CONSIDERATIONSPART I 164. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA."
        },
        {
            "id": "InternalMed_Harrison_6814",
            "title": "InternalMed_Harrison",
            "content": "No. of Study Therapy Patients ORR (%) PFS (months) Abbreviations: CbP, carboplatin and paclitaxel; CD, cisplatin and docetaxel; CG, cisplatin and gemcitabine; CP, cisplatin and paclitaxel; ORR, overall response rate; PFS, progression-free survival. EGFR, ALK rearrangements are typically (but not exclusively) associ-521 ated with younger age, light (<10 pack-year) and nonsmokers, and adenocarcinoma histology. Remarkably, ALK rearrangements were initially described in lung cancer in 2007, and by 2011, the first ALK inhibitor, crizotinib, received FDA approval for patients with lung tumors harboring ALK rearrangements."
        },
        {
            "id": "Surgery_Schwartz_4684",
            "title": "Surgery_Schwartz",
            "content": "2,18]Zhong 2012\u20130,16250,19388398110,8%0,85 [0,58, 1,24]Total (95% CI)611118431100,0%1,04 [0,92, 1,18]Heterogeneity: Tau2 = 0,00; Chi2 = 25,04, df = 26 (P = 0,52); I2 = 0%Test for overall effect: Z = 0,68 (P = 0,50)Forest plot of HR for overall survival impact of operative approach (segmentectomy versus lobectomy) of stage I NSCLC patients. The pooled HR displayed in this figure when compared with segmentectomy suggested that there was not a significant benefit of lobectomy on HR of stage I patients (7-21) (HR 1.04; 95% CI, 0.92\u20131.18, P = 0.50) (22\u201333).Abbreviations: HR = hazard ratio; NSCLC = non\u2013small cell lung cancer; CI = confidence interval; df = degree of freedom; SE = standard error.Reproduced with permission from Bedetti B, Bertolaccini L, Rocco R, et al: Segmentectomy versus lobectomy for stage I non-small cell lung cancer: a systematic review and meta-analysis, J Thorac Dis. 2017 Jun; 9(6):1615-1623.Brunicardi_Ch19_p0661-p0750.indd 69601/03/19 7:01 PM"
        },
        {
            "id": "InternalMed_Harrison_6684",
            "title": "InternalMed_Harrison",
            "content": "production. A rare germline mutation (T790M) involving the epidermal growth factor receptor (EGFR) maybe be linked to lung cancer susceptibility in never smokers. Likewise, a susceptibility locus on chromosome 6q greatly increases risk lung cancer risk among light and never smokers. Although progress has been made, there is a significant amount of work that remains to be done in identifying heritable risk factors for lung cancer. Currently no molecular criteria are suitable to select patients for more intense screening programs or for specific chemopreventative strategies."
        },
        {
            "id": "Pathology_Robbins_3287",
            "title": "Pathology_Robbins",
            "content": "Overall, squamous cell carcinoma and adenocarcinoma carry a more favorable prognosis than SCLC. When squamous cell carcinomas or adenocarcinomas are detected before metastasis or local spread (as in high-risk patients undergoing surveillance imaging), cure is possible by lobectomy or pneumonectomy. Unresectable adenocarcinomas associated with targetable mutations in tyrosine kinases such as EGFR may show remarkable responses to specific inhibitors. A few of these patients have long-term remissions on the order of years, but relapse within months to a year or so is typical. Inevitably, resistant tumors are found to have new mutations that either alter the drug target themselves (e.g., an additional mutation in EGFR that prevents drug binding) or circumvent tumor dependence on the drug target. Much effort is currently being devoted to understanding the mechanisms of targeted drug resistance in order to develop strategies that prevent it from occurring. Immune checkpoint inhibitors"
        },
        {
            "id": "InternalMed_Harrison_6165",
            "title": "InternalMed_Harrison",
            "content": "The evolution of tumor cells to a more malignant phenotype requires the acquisition of genetic changes that subvert apoptosis pathways and promote cancer cell survival and resistance to anticancer therapies. However, cancer cells may be more vulnerable than normal cells to therapeutic interventions that target the apoptosis pathways that cancer cells depend on. For instance, overexpression of Bcl-2 as a result of the t(14;18) translocation contributes to follicular lymphoma. Upregulation of Bcl-2 expression is also observed in prostate, breast, and lung cancers and melanoma. Targeting of antiapoptotic Bcl-2 family members has been accomplished by the identification of several low-molecular-weight compounds that bind to the hydrophobic pockets of either Bcl-2 or Bcl-XL and block their ability to associate with death-inducing BH3-only proteins. These compounds inhibit the antiapoptotic activities of Bcl-2 and Bcl-XL at nanomolar concentrations in the laboratory and are entering clinical"
        },
        {
            "id": "InternalMed_Harrison_6175",
            "title": "InternalMed_Harrison",
            "content": "The metastatic phenotype is likely restricted to a small fraction of tumor cells (Fig. 102e-6). A number of genetic and epigenetic changes are required for tumor cells to be able to metastasize, including activation of metastasis-promoting genes and inhibition of genes that suppress the metastatic ability. Cells with metastatic capability frequently express chemokine receptors that are likely important in the metastatic process. A number of candidate metastasis-suppressor genes have been identified, including genes coding for proteins that enhance apoptosis, suppress cell division, are involved in the interactions of cells with each other or the ECM, or suppress cell migration. The loss of function of these genes enhances metastasis. Gene expression profiling is being used to study the metastatic process and other properties of tumor cells that may predict susceptibilities."
        }
    ],
    "scores": [
        0.034651252259344005,
        0.024274262151179803,
        0.021885058337704343,
        0.021780091253775464,
        0.02142388921818907,
        0.020697342607454965,
        0.01973926372090262,
        0.01960972796308757,
        0.018978233495232956,
        0.018248197352674966,
        0.017740429505135387,
        0.017733835530445698,
        0.017593297791317596,
        0.017523722069176614,
        0.017220990391722098,
        0.017126269956458634,
        0.01702405099971023,
        0.01685159500693481,
        0.016372141372141373,
        0.01598746081504702,
        0.01588557516737675,
        0.015874015748031496,
        0.015109890109890112,
        0.014984960350013673,
        0.014984526847277267,
        0.014944444444444444,
        0.014938684503901897,
        0.01487173816895179,
        0.014836942992282796,
        0.014612811937226654,
        0.014572137246796197,
        0.014370920020664067
    ]
}